Aprea Therapeutics, Inc. (APRE) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US03836J2015
Aprea Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -13.23 m USD |
| EBIT | -12.60 m USD |
| Net income | -12.60 m USD |
| Diluted EPS – continuing operations | -1.93 USD |
Full history since 2007, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
More stocks
- NATURAL ALTERNATIVES INTERNATIONAL INC (NAII)
- GridAI Technologies Corp. (GRDX)
- Zoned Properties, Inc. (ZDPY)
- Alzamend Neuro, Inc. (ALZN)
- FLYWHEEL ADVANCED TECHNOLOGY, INC. (FWFW)
- NORTHERN MINERALS & EXPLORATION LTD. (NMEX)
- Purple Innovation, Inc. (PRPL)
- GAXOS.AI INC. (GXAI)
- BAB, INC. (BABB)
- INTELLIGENT BIO SOLUTIONS INC. (INBS)
- Crypto Co (CRCW)
- Acurx Pharmaceuticals, Inc. (ACXP)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.